Published Online: September 26, 2019. doi:10.1001/jamaoncol.2019.3140
Correction: This article was corrected on November 14, 2019, to add arrowheads to the Figure.
Corresponding Author: Sarthak Gupta, MD, National Institutes of Health, 10 Center Dr, Rm 5-5521, Bethesda, MD 20892-1930 (sarthak.gupta@nih.gov).
Conflict of Interest Disclosures: None reported.
Funding/Support: This research was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Cancer Institute of the National Institutes of Health.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the patient for granting permission to publish this information.
1.Weber
JS, Hodi
FS, Wolchok
JD,
et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.
J Clin Oncol. 2017;35(7):785-792.
PubMedGoogle ScholarCrossref 2.Richter
MD, Crowson
C, Kottschade
LA, Finnes
HD, Markovic
SN, Thanarajasingam
U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients.
Arthritis Rheumatol. 2019;71(3):468-475.
PubMedGoogle ScholarCrossref 3.Cappelli
LC, Gutierrez
AK, Baer
AN,
et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Ann Rheum Dis. 2017;76(1):43-50.
PubMedGoogle ScholarCrossref 4.Belkhir
R, Burel
SL, Dunogeant
L,
et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Ann Rheum Dis. 2017;76(10):1747-1750.
PubMedGoogle ScholarCrossref 5.de Velasco
G, Bermas
B, Choueiri
TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment.
Arthritis Rheumatol. 2016;68(2):556-557.
PubMedGoogle ScholarCrossref 6.Brahmer
JR, Lacchetti
C, Schneider
BJ,
et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 2018;36(17):1714-1768. doi:
10.1200/JCO.2017.77.6385PubMedGoogle ScholarCrossref 9.Schadendorf
D, Wolchok
JD, Hodi
FS,
et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials.
J Clin Oncol. 2017;35(34):3807-3814.
PubMedGoogle ScholarCrossref 10.Cappelli
LC, Brahmer
JR, Forde
PM,
et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Semin Arthritis Rheum. 2018;48(3):553-557.
PubMedGoogle ScholarCrossref